Literature DB >> 22266112

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Gulsun Erdag1, Jochen T Schaefer, Mark E Smolkin, Donna H Deacon, Sofia M Shea, Lynn T Dengel, James W Patterson, Craig L Slingluff.   

Abstract

Immune cells infiltrating the microenvironment of melanoma metastases may either limit or promote tumor progression, but the characteristics that distinguish these effects are obscure. In this study, we systematically evaluated the composition and organization of immune cells that infiltrated melanoma metastases in human patients. Three histologic patterns of immune cell infiltration were identified, designated immunotypes A, B, and C. Immunotype A was characterized by no immune cell infiltrate. Immunotype B was characterized by infiltration of immune cells limited only to regions proximal to intratumoral blood vessels. Immunotype C was characterized by a diffuse immune cell infiltrate throughout a metastatic tumor. These immunotypes represented 29%, 63%, and 8% of metastases with estimated median survival periods of 15, 23, and 130 months, respectively. Notably, from immunotypes A to C, there were increasing proportions of B cells and decreasing proportions of macrophages. Overall, the predominant immune cells were T cells (53%), B cell lineage cells (33%), and macrophages (13%), with natural killer and mature dendritic cells only rarely present. Whereas higher densities of CD8(+) T cells correlated best with survival, a higher density of CD45(+) leukocytes, T cells, and B cells also correlated with increased survival. Together, our findings reveal striking differences in the immune infiltrate in melanoma metastases in patients, suggesting microenvironmental differences in immune homing receptors and ligands that affect immune cell recruitment. These findings are important, not only by revealing how the immune microenvironment can affect outcomes but also because they reveal characteristics that may help improve individualized therapy for patients with metastatic melanoma.

Entities:  

Mesh:

Year:  2012        PMID: 22266112      PMCID: PMC3306813          DOI: 10.1158/0008-5472.CAN-11-3218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  B cells inhibit induction of T cell-dependent tumor immunity.

Authors:  Z Qin; G Richter; T Schüler; S Ibe; X Cao; T Blankenstein
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

2.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

Review 3.  Antitumor immunity at work in a melanoma patient.

Authors:  P G Coulie; H Ikeda; J F Baurain; R Chiari
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

4.  Inhibitory effects of B cells on antitumor immunity.

Authors:  Satoshi Inoue; Wolfgang W Leitner; Basil Golding; Dorothy Scott
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.

Authors:  Galina V Yamshchikov; David W Mullins; Chien-Chung Chang; Takeshi Ogino; Lee Thompson; Jennifer Presley; Holly Galavotti; William Aquila; Donna Deacon; William Ross; James W Patterson; Victor H Engelhard; Soldano Ferrone; Craig L Slingluff
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

6.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

7.  Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.

Authors:  Sangeeta Shah; Anagha A Divekar; Shannon P Hilchey; Hyun-Mi Cho; Corliss L Newman; Seung-Uon Shin; Hovav Nechustan; Pia M Challita-Eid; Benjamin M Segal; Kyung Hee Yi; Joseph D Rosenblatt
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

8.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.

Authors:  M C Mihm; C G Clemente; N Cascinelli
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

9.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.

Authors:  A Håkansson; B Gustafsson; L Krysander; L Håkansson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more
  237 in total

1.  Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Noah Sorrelle; Debolina Ganguly; Adrian T A Dominguez; Yuqing Zhang; Huocong Huang; Lekh N Dahal; Natalie Burton; Arturas Ziemys; Rolf A Brekken
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

2.  Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.

Authors:  Sook Jung Yun; Shujing Liu; Meghan Buckley; Tao Wang; Suna Jin; Giorgos Karakousis; Madalyn G Peters; David E Elder; Phyllis A Gimotty; Xiaowei Xu
Journal:  Hum Pathol       Date:  2019-04-06       Impact factor: 3.466

3.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Authors:  Katie M Leick; Joel Pinczewski; Ileana S Mauldin; Samuel J Young; Donna H Deacon; Amber N Woods; Marcus W Bosenberg; Victor H Engelhard; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2019-05-27       Impact factor: 6.968

Review 4.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

5.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

6.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Authors:  Ileana S Mauldin; Ena Wang; Donna H Deacon; Walter C Olson; Yongde Bao; Craig L Slingluff
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

8.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

9.  Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Mark E Smolkin; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja V Galeassi; Kimberly A Chianese-Bullock; Lynn T Dengel; Francesco M Marincola; Gina R Petroni; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

10.  Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja Galeassi; Jessica E Teague; Mark E Smolkin; Kimberly A Chianese-Bullock; Rachael A Clark; Gina R Petroni; Francesco M Marincola; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.